In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Engaging And Retaining Patients In Long-Term Observational Studies

Executive Summary

Success of long-term observational research studies depends on retaining participants; patient drop-out can lead to loss of vital data including endpoints. Study design considerations and direct-to-patient engagement strategies can help pharmas improve retention and compliance.

You may also be interested in...



Hybrid Studies: A Foundation For Comprehensive Evidence Development

Hybrid studies, which integrate prospective and existing health data, can generate evidence of drug and device safety and effectiveness through long-term patient follow-up in real-world settings.

A New Framework For Comprehensive Evidence Development

In today’s health care environment, where the volume and complexity of clinical information continues to increase for a range of stakeholders, research sponsors must understand how clinical trials, prospective observational research or registries, and retrospective data are used, what the costs are, and what a combined approach will look like. They must prepare for a more comprehensive and efficient research paradigm that provides payors, providers, and policy makers with the requisite data to make coverage and treatment decisions.

Using Enriched Studies For Post-Approval Evidence Needs

These days, clinical trial sponsors are being asked to provide empirical evidence to many stakeholders with diverse needs and to do so efficiently. By taking a holistic view of post-approval evidence needs, it is possible to address many stakeholders’ needs, thereby minimizing expense while increasing the likelihood of getting data that are fit for a variety of purposes.

Topics

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel